Changes in the national prevalence of asthma and coronavirus disease 2019 fatality: A population-based cross-sectional study.
Ann Allergy Asthma Immunol
; 131(2): 196-202, 2023 08.
Article
em En
| MEDLINE
| ID: mdl-37141944
ABSTRACT
BACKGROUND:
The coronavirus disease 2019 (COVID-19) mitigation and containment strategies implemented by each country can influence the prevalence of asthma and its fatality.OBJECTIVE:
To analyze the trend of asthma prevalence and COVID-19 fatality in children and adults with asthma.METHODS:
The prevalence of asthma and fatalities were compared among the peaks of 5 pandemic waves in Mexico.RESULTS:
Among patients with COVID-19, the prevalence rates of asthma among children were as follows wave I, 3.5%; wave II, 2.6%; wave III, 2.2%; wave IV, 2.4%; and wave V, 1.9% (P for trend < .001); the prevalence rates of asthma among adults were as follows wave I, 2.5%; wave II, 1.8%; wave III, 1.5%; wave IV, 1.7%; and wave V, 1.6% (P for trend < .001). The rates of fatality because of COVID-19 among individuals with asthma were as follows wave I, 8.9%; wave II, 7.7%; wave III, 5.0%; wave IV, 0.9%; and wave V, 0.2% (P for trend < .001).CONCLUSION:
The prevalence rates of asthma and fatalities from COVID-19 suggest a gradual reduction throughout the pandemic in Mexico.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Asma
/
COVID-19
Tipo de estudo:
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limite:
Adult
/
Child
/
Humans
Idioma:
En
Revista:
Ann Allergy Asthma Immunol
Assunto da revista:
ALERGIA E IMUNOLOGIA
Ano de publicação:
2023
Tipo de documento:
Article